N Engl J Med 2011 Dec 29
A phase 3 trial of bevacizumab in ovarian cancer.
Related Questions
When prescribing bevacizumab for high-risk primary ovarian cancer, do you use 15 mg/m2 q 21 days (per GOG-0218) or 7.5 mg/m2 q 21 days (per ICON7)?
Interesting question. I was told once when bevacizumab was being developed by Genentech that the basic scientists predicted 5 mg/kg would saturate all the VEGF receptors in a typical adult (unconfirmed but told by someone in my remote past...I should confirm with Genentech). How 15 mg/kg was arrived...
For an optimally cytoreduced, stage III ovarian carcinosarcoma, would you offer bevacizumab maintenance after completion of adjuvant carboplatin/taxol?
For an optimally cytoreduced patient with Stage III ovarian carcinosarcoma, I would not add bevacizumab unless the patient was "optimal" at interval surgery and had neoadjuvant and adjuvant use of bevacizumab with chemo and then to be continued in maintenance. The use of bevacizumab with chemo in th...
What pre-treatment findings on CT scan (if any) influence your concern for GI perforation risk with bevacizumab use in ovarian cancer patients?
This is really a two parts question. The first question would be, do you offer bevacizumab to all your ovarian cancer patients and the second question would be what patients would you not recommend bevacizumab because of concern for bowel perforation? Based on findings from GOG218 and ICON7, I only ...
In light of GOG-252, are there any situations where IP chemotherapy would be preferable following debulking of advanced epithelial ovarian cancer?
In GOG-252, the control arm (arm 1) was the dose-dense Japanese GOG (JGOG) regimen, compared to two IP-based arms (arm 2, IP carboplatin, and arm 3, IP cisplatin). As stated in our OGR, interpretation of the negative results of this study is difficult for several reasons. All three arms in GOG-252 r...
How do you manage maintenance therapy in BRCA wild type patients who have undergone primary surgery and achieved an optimal/complete gross resection?
I do not personally utilize maintenance bevacizumab in the upfront setting for wtBRCA patients who had primary optimal resection as I do not think the small PFS benefit demonstrated in GOG 218 and ICON 7 (evaluating use of maintenance bev vs no maintenance) justifies the additional cost and morbidit...
Should women with adequately debulked ovarian cancer receive bevacizumab with chemotherapy in the adjuvant setting?
The answer to this question is definitively NO.Two large, definitive studies (ICON-7 and GOG218 – including over 3400 patient combined) evaluated the impact of adjuvant chemotherapy with concurrent + maintenance bevacizumab. Analysis of mature data from ICON-7 demonstrated a significant overall surv...